x
Filter:
Filters applied
- Congenital: Fontan
- D'Udekem, YvesRemove D'Udekem, Yves filter
Publication Date
Please choose a date range between 2019 and 2021.
Author
- Cordina, Rachael2
- Iyengar, Ajay J2
- Alphonso, Nelson1
- Attard, Chantal1
- Betts, Kim S1
- Briody, Julie1
- Bullock, Andrew1
- Burchill, Luke1
- Celermajer, David S1
- Du Plessis, Karin1
- Gentles, Thomas1
- Hassan, Ebrahim Bani1
- Ignjatovic, Vera1
- Justo, Robert1
- Justo, Robert N1
- King, Gregory1
- Mackay, Mark T1
- Marathe, Supreet P1
- Monagle, Paul T1
- Rice, Kathryn1
- Salve, Gananjay G1
- Sharma, Varun J1
- Simm, Peter1
- Venugopal, Prem1
Congenital: Fontan
4 Results
- Congenital: Fontan
Long-term outcomes of warfarin versus aspirin after Fontan surgery
The Journal of Thoracic and Cardiovascular SurgeryVol. 162Issue 4p1218–1228.e3Published online: January 4, 2021- Chantal Attard
- Paul T. Monagle
- Yves d'Udekem
- Mark T. Mackay
- Julie Briody
- Rachael Cordina
- and others
Cited in Scopus: 11Because of the nature of the Fontan physiology, patients are at an increased risk of thromboembolic complications. As such, warfarin or aspirin is generally prescribed lifelong for thromboprophylaxis. This study aimed to compare long-term rates of cerebrovascular injury, thrombosis, bleeding, bone mineral density, and quality of life in people living with Fontan circulation receiving warfarin compared with aspirin. - Congenital: FontanOpen Archive
Long-term outcomes following Fontan takedown in Australia and New Zealand
The Journal of Thoracic and Cardiovascular SurgeryVol. 161Issue 3p1126–1135Published online: October 5, 2020- Supreet P. Marathe
- Ajay J. Iyengar
- Kim S. Betts
- Karin du Plessis
- Gananjay G. Salve
- Robert N. Justo
- and others
Cited in Scopus: 3Fontan takedown remains an option for the management of Fontan failure. We sought to evaluate early and late outcomes after Fontan takedown. - Congenital: Fontan
Protein-losing enteropathy and plastic bronchitis after the Fontan procedure
The Journal of Thoracic and Cardiovascular SurgeryVol. 161Issue 6p2158–2165.e4Published online: August 11, 2020- Varun J. Sharma
- Ajay J. Iyengar
- Diana Zannino
- Thomas Gentles
- Robert Justo
- David S. Celermajer
- and others
Cited in Scopus: 15Protein losing enteropathy and plastic bronchitis are severe complications in Fontan circulation, with 5-year survival ranging from 46% to 88%. We report risk factors and outcomes of protein losing enteropathy and plastic bronchitis in patients undergoing the Fontan. - CommentaryOpen Archive
Commentary: Moderate atrioventricular valve regurgitation may be too much to bear for a single ventricle
The Journal of Thoracic and Cardiovascular SurgeryVol. 158Issue 6p1649–1651Published online: September 19, 2019- Gregory King
- Yves d'Udekem
Cited in Scopus: 2In their editorial review in this issue of the Journal, Stephens and Dearani1 comment on the results of our retrospective series2 that assessed the incidence and impact of atrioventricular regurgitation in patients who had survived the Fontan operation. In our experience, more than half of the common atrioventricular valves and tricuspid valves were regurgitant or necessitated intervention before patients reached the age of 25 years (Figure 1).2 The existence of even moderate regurgitation was enough to more than double a patient's risk of circulatory failure, which for most meant death or transplantation.